4-fluoro-5-methylisoxazol-3-ol | 131573-78-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-fluoro-5-methylisoxazol-3-ol
• 英文别名: 4-fluoro-5-methyl-1,2-oxazol-3-one
• CAS: 131573-78-9
• 化学式: C₄H₄FNO₂
• 分子量: 117.08
• InChiKey: LWDJOADQGRUILB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzhydryl 3-(hydroxymethyl)-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 、 4-fluoro-5-methylisoxazol-3-ol 生成 benzhydryl 3-[(4-fluoro-5-methyl-1,2-oxazol-3-yl)oxymethyl]-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  参考文献：
  名称：

  NAKAYAMA, EIJI;WATANABE, KATSUHIKO;MIYAUCHI, MASAO;FUJIMOTO, KOICHI;IDE, +, J. ANTIBIOTICS, 43,(1990) N, C. 1122-1130

  摘要：

  DOI：
• 作为产物：
  描述：

  2-fluoro-2-(2-methyl-1,3-dioxolan-2-yl)ethanehydroxamic acid 在 硫酸 作用下， 生成 4-fluoro-5-methylisoxazol-3-ol
  参考文献：
  名称：

  BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

  摘要：

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。

  公开号：

  US20190300521A1

文献信息

• [EN] TROPANE DERIVATIVES AND THEIR USE AS ACE INHIBITORS<br/>[FR] DERIVES DE TROPANE ET LEUR UTILISATION COMME INHIBITEURS D'ACE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004096799A1

  公开（公告）日：2004-11-11

  The invention relates to novel tropane derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  本发明涉及新型的莨菪衍生物及相关化合物，以及它们作为活性成分在制备药物组合物中的用途。本发明还涉及相关方面，包括制备这些化合物的过程，含有一种或多种这些化合物的药物组合物，尤其是它们作为肾素抑制剂的用途。
• BICYCLIC COMPOUND
  申请人：YASUMA TSUNEO

  公开号：US20120142714A1

  公开（公告）日：2012-06-07

  The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有ACC抑制作用的化合物，该化合物可用作预防或治疗肥胖症、糖尿病等疾病的药物，并具有优越的功效。本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中定义的，或其盐。
• Bicyclic compound
  申请人：Yasuma Tsuneo

  公开号：US08729102B2

  公开（公告）日：2014-05-20

  The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有ACC抑制作用的化合物，可用作预防或治疗肥胖症、糖尿病等药物，并具有卓越的疗效。本发明涉及一种由式（I）表示的化合物：其中每个符号如规范中所定义，或其盐。
• NAKAYAMA, EIJI;WATANABE, KATSUHIKO;MIYAUCHI, MASAO;FUJIMOTO, KOICHI;IDE, +, J. ANTIBIOTICS, 43,(1990) N, C. 1122-1130
  作者：NAKAYAMA, EIJI、WATANABE, KATSUHIKO、MIYAUCHI, MASAO、FUJIMOTO, KOICHI、IDE, +

  DOI：——

  日期：——
• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。